Lentiviral Vector Manufacturing: Old But Gold Gene Therapy Viruses?

Lentiviral vectors have reemerged as essential tools in gene therapy, driven by improved safety profiles and successful clinical outcomes. Their unique ability to transduce both dividing and non-dividing cells, combined with larger cargo capacity compared to AAV, makes them particularly valuable for treating genetic diseases and cancers.

Discover how modern manufacturing addresses critical production challenges, from plasmid-based vector assembly through transfection protocols to harvest and purification workflows. The complexities of maintaining product integrity during processing require sophisticated approaches to aseptic filling and controlled freezing; aggregation during freeze-thaw cycles remains a persistent challenge that demands precise temperature control. Learn how automated platform systems enable scalable production from clinical to commercial batches while minimizing contamination risks.

As ex vivo cell modification and potential in vivo editing applications expand, understanding the manufacturing infrastructure behind these HIV-derived delivery systems becomes increasingly critical for advancing next-generation therapeutics.